KiraGen Bio

KiraGen Bio is pioneering the next wave of cancer treatment through AI-driven, multiplex gene-edited CAR-T cell therapies, targeting the challenging realm of solid tumors. Despite the transformative success of cell therapies in hematologic cancers, solid tumors — which constitute the majority of cancer cases — have remained elusive to current treatments due to their complex tumor microenvironment (TME). Our mission is to breach this final frontier, leveraging our proprietary AI platform and combinatorial gene editing to design CAR-T cells capable of overcoming the immunosuppressive barriers of the TME. Founded on the belief that every cancer patient deserves a chance at a cure, KiraGen Bio combines the latest in biotechnology and computational science to bring innovative therapies from the lab to the clinic. Our team, comprised of experts in oncology, immunology, gene editing, and artificial intelligence, is dedicated to creating effective, durable treatments for solid tumors. KiraGen Bio stands at the intersection of innovation and hope, where cutting-edge science meets the urgent need for more effective cancer treatments. Our integrated approach spans from discovery through clinical development, embodying a commitment to excellence, patient-centricity, and the relentless pursuit of curing cancer. Join us as we work to transform the landscape of cancer therapy and bring new hope to millions of patients worldwide.